China-Biotics, Inc. (CHBT)

[mlkrborn]

Red flag Chinese small caps: CHBT mentioned!
http://www.fool.com/investing/international/2011/06/07/still-the-no-1-chinese-small-cap-red-flag.aspx

[ScotiaNostra]

Mate time for you to come back to #PCFG ... she's about to blow ... might take a week or two but as I recall that's where we first 'met' and I've been there ever since ....

[1millman]

Anyone have a feeling on this one? I noticed that 4M shares were bought by insider, Value Holdings Capital, over the past few weeks at a pps between $8.01 and $11.56. Figured I would take a shot at it this afternoon just for that reason and picked up some shares.

[mlkrborn]

CHBT $5.21 after $0.83 cents..Maxim group, its constant supporter, downgraded it to sell as Surf reported earlier..no other significant news!

[surf1944]

China-Biotics CHBT Maxim Group Hold » Sell $6

Read more: http://www.briefing.com/investor/calendars/upgrades-downgrades/#ixzz1O26iap1p

[viking86]

China-Biotics Receives First U.S. Sales Order:

The U.S. based nutritional product company placed its first sales order, and formally entered into its agreement with China-Biotics on March 28, 2011. The agreement is effective for two years beginning on March 17, 2011, the day after the parties entered into an agreement in principle.

Mr. Jinan Song, CEO and Chairman of China-Biotics, commented, "We are excited to have received our first product sales order quickly after having established a business relationship with our U.S. customer. While continuing to increase our market share domestically, we also look forward to future growth opportunities in the international market."

http://finance.yahoo.com/news/ChinaBiotics-Receives-First-prnews-420994357.html?x=0&.v=1

[viking86]

chart: nice bullish pattern yesterday, gapped up today.

[viking86]

Short Interest as of Mar 15, 2011 vs. 2 prior periods:

3/15/2011 3,788,200 471,143 8.040446
2/28/2011 3,743,404 484,304 7.729451
2/15/2011 3,372,818 378,951 8.900407


http://www.nasdaq.com/aspxcontent/shortinterests.aspx?symbol=CHBT&symbol=CCME&selected=CHBT

[viking86]

Roth suspends coverage of CHBT.

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=61202965

[JB3729]

You'd think that he could get 1 out of 3 right.

G/L

[YngvaiMalmsteve]

The author, Sean Wright, is the same person who was bullish on CCME (recently halted due to fraud suspicion) and CEU (also suspected of fraud and is now trading down in the dumps).

The fact that Sean is bullish on this stock should set off a lot of alarms.

[JB3729]

SA article, very bullish.

http://seekingalpha.com/article/258723-china-biotics-executing-solidly-on-growth-plans-means-great-things-to-come?source=email_investment_ideas

G/L

[Bluewave]

Why is New Customer not named????????


This isn't right. This is not a security product.

Until the actul U.S. customer comes forward and makes their own announcment of a contract with China Biotics I'm guessing their either is no contract or it is going to be very disappointing about what the contract is for.

[viking86]

nice, it's their first overseas customer in a market dominated by European probiotics producers. It's a small step forward in a major direction IMO.


We are confident that this is just the start of our future expansion in the international market

[bUrRpPPP!]

China-Biotics Wins First US Customer

{possibly fluff news imo...could be as little as one person with a juice stand in California buying one order...poor choice to release something as hollow as this with no name or dollar amount..is it a recurring contract?...whats an agreement? ..etc etc}



SHANGHAI, March 18, 2011 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc. (Nasdaq: CHBT) ("China-Biotics" or "the Company"), the leading developer, manufacturer and distributor of probiotics products in China, today announced that the Company has entered into an agreement with a US based nutritional product company.

This new contract marks the major milestone in the China-Biotics' corporate history as it is the first contract win outside of China. The company's R&D representatives recently attended Natural Product Expo West in Anaheim, California, which attracted approximately 3400 exhibitors and a wide array of health food industry participants.

Mr. Jinan Song, CEO and Chairman of China-Biotics, commented, "we are very excited about winning our first overseas customer, in a market which not only carries the world's leading standard in food safety but also consumes large volume and varieties of health food. This is a solid testimony that our product quality and technology capability have been received by the international market. With this new win, we are now officially a new contender for the US market, which is historically dominated by European probiotics producers. We are confident that this is just the start of our future expansion in the international market."

[bUrRpPPP!]

Bright food group website...

http://www.brightfood.com/en/company/Bright.asp

[bUrRpPPP!]

CHBT Presentation

http://www.chn-biotics.com/c4429/c4459/

[bUrRpPPP!]

The Street downgrades CHBT...looks like the noose is tightening on the next victim....

http://www.thestreet.com/story/11050709/1/china-biotics-inc-stock-downgraded-chbt.html

China-biotics (Nasdaq:CHBT) has been downgraded by TheStreet Ratings from buy to hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and growth in earnings per share. However, as a counter to these strengths, we also find weaknesses including weak operating cash flow and a generally disappointing performance in the stock itself.
Highlights from the ratings report include:
Net operating cash flow has decreased to $1.61 million or 43.03% when compared to the same quarter last year. In addition, when comparing the cash generation rate to the industry average, the firm's growth is significantly lower.
CHBT's stock share price has done very poorly compared to where it was a year ago: Despite any rallies, the net result is that it is down by 52.83%, which is also worse that the performance of the S&P 500 Index. Investors have so far failed to pay much attention to the earnings improvements the company has managed to achieve over the last quarter. Naturally, the overall market trend is bound to be a significant factor. However, in one sense, the stock's sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.
The net income growth from the same quarter one year ago has exceeded that of the Personal Products industry average, but is less than that of the S&P 500. The net income increased by 26.6% when compared to the same quarter one year prior, rising from $10.48 million to $13.26 million.
CHBT has no debt to speak of therefore resulting in a debt-to-equity ratio of zero, which we consider to be a relatively favorable sign. Along with this, the company maintains a quick ratio of 4.05, which clearly demonstrates the ability to cover short-term cash needs.
The revenue growth greatly exceeded the industry average of 3.0%. Since the same quarter one year prior, revenues rose by 39.0%. Growth in the company's revenue appears to have helped boost the earnings per share.
China-Biotics, Inc. engages in the research, development, production, marketing, and distribution of probiotics products in the People's Republic of China. Its products contain live microbial food supplements, which beneficially affect the host by improving its intestinal microbial balance. The company has a P/E ratio of seven, equal to the average drugs industry P/E ratio and below the S&P 500 P/E ratio of 15.9. China-biotics has a market cap of $199.8 million and is part of the health care sector and drugs industry. Shares are down 45.5% year to date as of the close of trading on Wednesday.

[viking86]

China-Biotics Expands Product Supplied to Bright Dairy: this is Mgmt's way of responding to allegations that their bulk customers deny having business with CHBT.


SHANGHAI, March 17, 2011 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc. (Nasdaq: CHBT) ("China-Biotics" or "the Company"), the leading developer, manufacturer and distributor of probiotics products in China, today announced that the Company has expanded its categories of strain formula supplied to Bright Dairy.

China-Biotics has recently added 3 new strain formulas that it supplies to Bright Dairy, one of the top 3 dairy enterprises in China. These new formulas will be used in Bright Dairy's highly anticipated premium yogurt product lines.

This expansion of supplied formula is a direct reflection of the Company's GMP-certified production techniques, technical safety and quality assurance, as Bright Dairy maintains one of the most stringent inspection processes in the industry.

Mr. Jinan Song, CEO and Chairman of CHBT, commented, "We are very pleased to have expanded our products supplied to Bright Dairy, a top three dairy producer in China. Our undivided efforts on R&D and developing customized solutions for different dairy companies are starting to pay off. We remain focused on transitioning to our B2B business model and intend to expand our market share in China."

"Our current stock price does not reflect our long-term value and premium product quality in a large addressable market capable of sustaining rapid growth. Management will continue to focus on optimizing business operations and market expansion. We remain confident that, in the long run, our strategic position and ability to create value will be recognized by the US investment community."

[JB3729]

Bought a few Jan calls.

JB

[bUrRpPPP!]

Heavy put activity today..possible HIT coming?

[viking86]

CHBT to present today (at 12:20PM) at the Rodman & Renshaw Annual China Investment Conference:


http://www.meetmax.com/sched/event_7919/~public/conference_presentations.html?event_id=7919

[bUrRpPPP!]

CHBT very bullish stock analysis...

http://www.nasdaq.com/asp/stock_consultant.asp?symbol=CHBT&selected=CHBT

[viking86]

CHBT filed 5 new patents as a direct result of its increased R&D efforts. Now they have a 40-man strong R&D team devoted to bump this company up to top R&D standards and rapidly increase its market share in probiotics acc. to most recent 10Q:

Research and development (R&D) expenses increased to $1.9 million from $0.8 million in the third quarter of fiscal year 2010. R&D expenses as a percentage of revenue were 5.8%, as compared to 3.3% for the third quarter of fiscal year 2010. The Company established a strong research and development team supported by over 10 PhDs and 30 masters' degree holders. Dr. Chungchang Tao, formerly with Coca-Cola's Global Innovation & Technology Center in Shanghai, joined the Company as its R&D Director. Dr. Tao holds a PhD in Biological & Agricultural Engineering from the University of Idaho. In addition, the number of probiotics strains in the Company's proprietary strain library has now increased to over 1,000. The Company will continue to invest in its core technology of bacteria cultures and preservation, while expanding its product line and applications to address specific health problems.

http://finance.yahoo.com/news/ChinaBiotics-Files-for-5-New-prnews-1988181149.html?x=0&.v=1

[viking86]

whoa.. just got home from work, the stock looks like it was run over by a bulldozer...I don't see any bad news anywhere.. yet

[BigOnChina]

Absolutely nothing happened. Looked like someone got caught with a margin call (or something) and had to dump shares on the cheap.

[chrich12]

Anyone know what happened today? I'm travelling and just looked at CHBT and saw the big drop. TIA.

[viking86]

New Institutional Hodlings report as of 12/31/10: many additions, Wellington still #1 added another 54K shares, DE Shaw #2 added 73K shares, new #5 is Cubic Asset with a new postion of 214K, Calpers added 75K.

http://www.nasdaq.com/asp/holdings.asp?symbol=CHBT&symbol=CCME&symbol=UTA&selected=CHBT&FormType=Institutional

[appfan]

I agree; but it comes with the territory for now, until all of the RTO's have vetted themselves and armor plated themselves against Citron/Muddy Waters it will be like this. Let's hope that CHBT gets back to 20ish in the next 3 to 6 months.

[BigOnChina]

unfortunately, I'm pretty sure you may get another chance to buy at sub 13.00 again.

I hate that china companies have to waste so much of their management time answering fraud allegations. I don't want them dealing with legal people (also a waste of money) or answering every internet blog writer. I want them running the company!

[appfan]

As long as the shorts see that they have the ability to drive stock price down, they won't give up. CHBT needs to continue to stay aggressive on dispelling the current 5 allegations. It is easy for a shorter to keep pouncing on the same items over and over again, even though there has been proof, showing the allegations are not true. Any shareholder that believes the "long" story, should find these prices attractive for 6 to 12 month investment. If you believe shorts can drive it down further, then wait. I'm sorry I missed the sub-13 price today.

[BigOnChina]

Another hit piece out this morning. When does it end?

insert-text-here

[BigOnChina]

The only way to play this space is to diversify your investment between 15-20 small cap stocks and sit on it for years. Sure, we can trade in and out over short periods of time but the basis of the theory is that china is growing, and fast, and these stocks will appreciate with that growth.

[viking86]

some new stats: Short Interest and Institutional Holdings

Short Interest
1/31/2011 3,441,954
1/14/2011 3,325,666

http://www.nasdaq.com/aspxcontent/shortinterests.aspx?symbol=CCME&symbol=HRBN&symbol=CHBT&symbol=NEP&symbol=CHGS&symbol=AUTC&symbol=KONE&symbol=BSPM&symbol=CSR&symbol=NFLX&symbol=YONG&symbol=OREX&selected=CHBT


Institutions and Mutual Funds = 107
Top 50 Holders = 23.25% of Outstanding Shares

http://www.dailyfinance.com/company/china-biotics-inc/chbt/nas/institutional-ownership

[viking86]

There's a chinese proverb that says: "the most endangered place is also the safest place" . Seems like NathanGreene is taking that to heart with his post today on CGS:

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=59734483

basically all CGS stocks are prone for those short attacks except those that already have been hit (?). If that's true, then four of my stocks are relative "safe havens": CHBT, CCME, TSTC, UTA, eh?

[Florinda]

BigOnChina,

Wow, I hope your right about that! I'm too busy to be jumping in and out of stocks too much, so I'm assuming that sooner or later this sector will come around again. Many of my holdings are at or near lows for the year: CKGT, NEP, BSPM, XNYH, LTUS, and others toying with bottoms like YONG and HFGB. So for me I've more or less resigned to ride it out and just hope that none of the stocks we own are frauds. If not, then they "should" do well in time. However, I'm 100% in on Chinese small caps. If and when it turns I might re-think this stance to some extent. Never should have sold MELI, for instance. But, no matter, can't always be right about anything!

Thanks for your further comments,

Steve

[BigOnChina]

Great points. I agree with almost everything that you said except one thing...I think if the S&P corrects, it may be good for the emerging markets and china in particular. I think alot of money has left the china small cap space because investors think they can see better returns in a safer US market. If those investors start to pull out that money from the Microsoft's and Cisco's of the world, they're going to be looking for someplace to park it. NEP, CHBT, LPH, UTA, and CCME will be right at the top of their lists.

[Florinda]

BigOnChina, I hope this isn't a foretaste of what's to come with all the Chinese earning releases set to come out over the next 6 weeks or so. Unfortunately, though, I suspect a lot of people are itching to get out of their China holdings and will use good earnings to do so. With the headwinds as strong as they are for this sector, and with many pounding the table about an overdue correction for the markets in general, those of us still holding (NEP!) will probably get it handed to us.

If there's any truth to the old saying that when everyone is running for cover is the time to buy, then perhaps we're very near the bottom. Don't really have much of a feel for it myself though. No money to act on it anyway. Just hope all the hub hub from the hit pieces doesn't turn this sector into a worthless graveyard. Given how dead this sector has been--at least in the little universe of stocks I follow--I was surprised to see a SA article two days ago wherein the author was recommending shorting the entire Chinese small cap sector--which he himself had claimed to have done--because of inflation worries and the negative effects that that will have on China. So, are we really near a bottom? If the S&P corrects it seems unlikely that this most vulnerable of sectors won't follow suit save perhaps a few exceptions.

Good luck to all. Also, thanks a lot, Viking, for distilling the numbers again. Much appreciated.

Steve

[viking86]

I am not really surprised about today's 5% drop despite strong earnings. Usual stuff with many CGS stocks imo: traders move in a few days before E/R and sell on the news. Same thing with CCME, reported a huge Q3 on Nov 9, Net Inc grew yoy over 150%, stock tanked 25% within a week, from a high of 21.25 the day before E/R to a low of 15.9 on Nov 16 (shrug).

http://finance.yahoo.com/echarts?s=CCME+Interactive#chart2:symbol=ccme;range=6m;indicator=volume;charttype=candlestick;crosshair=on;ohlcvalues=0;logscale=on;source=undefined

[bogey999]

Another chunk taken out of my ass, this is getting old.

[BigOnChina]

I can't believe the stock dropped on today's earnings report. That's just plain strange to me. I hope CHBT decides to buy back shares.

[viking86]

just listened to the CC and here are a few points I was able to understand from the Q&A section:

- auditor: no plan to switch auditor currently as Company is pleased with the cuurent one, good working relationship, high-quality professional work

- Q3 Bulk sales was $14.7MM, that's 45% of total sales, a new record high for the company. 20 tons sold reported.

-retail sales was 18.1M (?), 94.5% of it came from the distributors

- Yangling status: land use rights are now all paid, they are working on design & construction of the plant and equipment and expect to start production in about 24 months.

- cash balances reported have been audited, free cash flow was 5.2MM

- Dupont buyout offer of Danisco being rejected: Dupont trying mainly to boost its profile in the US market with the Danisco proposed buyout.


As far as the Q3 results, there is an error in the fd sharecount as presented in PR (22,370,000). It should be 23,871,000 as in 10Q. With an adj Net Income of $10,416,229, the adj (non GAAP) eps should be 0.44 (not 0.466 as in PR). That's a 44.5% yoy growth. I get a ttm eps of $1.523.

http://finance.yahoo.com/news/ChinaBiotics-Inc-Reports-prnews-2162131020.html?x=0&.v=1

[BigOnChina]

50% expected growth this year, a solid earnings report, and the stock falls?

[bUrRpPPP!]

China-Biotics Backs FY11 Expectation For Net Sales To Achieve At Least 50% Yr-Over-Yr Growth>CHBT

[bogey999]

well nuts, was thinking earnings were going to be during market hours...

pretty good stuff so far

[bUrRpPPP!]

Hi Viking so what eps range are you thinking?

[viking86]

Dial info for E/R CC Wed 2/09 8AM:

SHANGHAI, Jan. 31, 2011 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc. ("China-Biotics", the "Company") (Nasdaq:CHBT - News), the leading developer, manufacturer and distributor of probiotics products in China, today announced it will host a conference call at 08:00 a.m. Eastern Time/09:00 p.m. Beijing Time on Wednesday, February 9, 2011, to discuss the fiscal year 2011 third quarter financial results for the period ended December 31, 2010.

The telephone numbers for the conference call are [phone] (U.S.) or [phone] (International), passcode: 68499662. A live web cast of the call will also be available on the investor relations section of the Company's website www.chn-biotics.com. To listen to the web cast, please visit the site at least 10 minutes early to register, download and install any necessary audio software.The replay of the web cast will be archived on the website, and investors will be able to access the recording of the conference call until midnight ET on February 16, 2011 by calling [phone] (U.S.) or [phone] (International) and entering passcode: 95179753.

[bUrRpPPP!]

Sure is a lot of overlapping names....eom

[bUrRpPPP!]

Vitamin maker Royal DSM makes $1.1 billion offer for Md.-based Martek
Tuesday, December 21, 2010; 7:22 PM

Martek, a Columbia-based maker of nutrients for baby formula and other products, said Tuesday that it has accepted a nearly $1.1 billion buyout offer from the world's largest vitamin supplier.

Martek's executives and board of directors have endorsed the deal, but it needs the approval of shareholders and regulators. Executives expect the transaction will close in the first half of next year.

The buyout offer from Netherlands-based Royal DSM equates to $31.50 a share of Martek, a 35 percent premium on the company's closing price Monday. The stock soared $8.31, or 35.6 percent, to close at $31.67 Tuesday after the offer was announced.

The deal will allow Martek to sell more of its products globally and will give DSM a larger footprint in the United States, the companies said in a statement. For the fiscal year that ended Oct. 31, Martek reported a profit of $27.9 million, a 31 percent decline from the year before.

"We are pleased that this transaction appropriately recognizes the value of Martek's nutritional ingredients, technology platform, market position and skilled workforce, while providing significant value to our stockholders," chief executive Steve Dubin said in a statement. "We have worked collaboratively with DSM for many years, and we are confident that they share our vision for Martek's future."
ad_icon

Founded 25 years ago, Martek has deep roots in the Maryland biotech community, and about 220 of its 525 employees work at its Columbia headquarters.

The company's flagship product, DHA, is an omega-3 fatty acid that is thought to improve brain and eye development in babies and to promote overall human health. The nutrient is added to nearly all infant formula in the United States and many international markets.

Martek has also expanded into other consumer products and brands, including food and beverages sold by Quiznos and Minute Maid. In February the company bought Amerifit, which develops and markets consumer health products, for $200 million.

Renee Winsky, chief executive of the Tech Council of Maryland, called the acquisition a win for the state's biotechnology industry. DSM's entry into the region will give the industry additional clout and another international partner with which to do business, she said.

"One could argue there is an even bigger player in town now when you add in the assets of this global company. . . . It makes [Martek] all the more powerful and our biotech community all the stronger," Winsky said. "One would hope that every biotech company in incubators in Maryland could be that lucky and that successful."